

the company's business operations and financial performance. The company's business operations and financial performance are subject to various risks, including market risk, credit risk, and operational risk. The company's business operations and financial performance are subject to various risks, including market risk, credit risk, and operational risk.



2 FINANCIAL HIGHLIGHTS

2.1 Principal Financial Data and Indicators

		For the year ended December 31,	
		2023	2022
		(R MB'000)	(Z'000)
Revenue		1,596,266	1,484,903
Operating expenses		99,182	15,605
Operating income		12,250	26,574
Finance income		86,932	-10,969
Finance expenses		85,948	-24,221
Income before income taxes		984	13,252
Income taxes			
Income after income taxes			
Net income			
Other comprehensive income			
Comprehensive income			
Assets			
Assets under management		3,047,687	2,637,787
Assets under administration		1,639,481	1,311,885
Assets under custody		1,408,206	1,325,903
Assets under management, administration and custody		1,265,065	1,201,585
Other assets	124,318		
Total assets			
Liabilities			
Liabilities under management			
Liabilities under administration			
Liabilities under custody			
Liabilities under management, administration and custody			
Other liabilities			
Total liabilities			
Equity			
Equity under management			
Equity under administration			
Equity under custody			
Equity under management, administration and custody			
Other equity			
Total equity			
Total liabilities and equity			

For the year ended

December 31,

2023

2022

(R MB'000)

(Z'000)

Revenue	227,221
Operating expenses	-273,615
Operating income	-215,017
Finance income	96,107
Finance expenses	116,178
Income before income taxes	
Income taxes	
Income after income taxes	
Net income	
Other comprehensive income	
Comprehensive income	

3.3 Business Outlook

2023, compared to 2022, the increase was primarily due to the increase in the number of patients treated at the hospitals, which was 7.9% (2022, 5.9%).

	For the year ended December 31,	
	2023 (R MB'000)	2022 (R '000)
Billing revenue from owned hospitals	1,537,406	1,425,005
Other revenue	52,245	58,188
	<u>1,485,161</u>	<u>1,366,817</u>

2023, compared to 2022, the increase was primarily due to the increase in the number of patients treated at the hospitals, which was 7.9% (2022, 5.9%). The increase in the number of patients treated at the hospitals was primarily due to the increase in the number of patients treated at the hospitals, which was 7.9% (2022, 5.9%).

2023, compared to 2022, the increase was primarily due to the increase in the number of patients treated at the hospitals, which was 7.9% (2022, 5.9%).

	For the year ended December 31,	
	2023 (R MB'000)	2022 (R '000)
Billing revenue from owned hospitals	1,537,406	1,425,005
Other revenue	1,107,920	1,040,115
	429,486	384,890

2023, compared to 2022, the increase was primarily due to the increase in the number of patients treated at the hospitals, which was 7.9% (2022, 5.9%). The increase in the number of patients treated at the hospitals was primarily due to the increase in the number of patients treated at the hospitals, which was 7.9% (2022, 5.9%).

the year ended 31 December 2022, the Group's revenue from pharmaceutical sales was R305,118,000, an increase of 1.9% from R302,000,000 in the year ended 31 December 2021.

	For the year ended December 31,	
	2023	2022
Inpatients		
Number of inpatient bed-days	11,268	9,688
Revenue from inpatient services (R'000)	4,112,820	3,536,120
Average inpatient spending per bed-day (%)	84.4	88.7
Revenue from pharmaceutical sales (R'000)	3,471,366	3,134,950
Revenue from pharmaceutical sales as a percentage of total inpatient revenue (R'000)	1,146,473	1,061,798
Revenue from pharmaceutical sales as a percentage of total inpatient revenue (%)	330	339
Revenue from pharmaceutical sales as a percentage of total inpatient revenue (R'000)	172,590	156,512
Revenue from pharmaceutical sales as a percentage of total inpatient revenue (%)	50	50
Total inpatient revenue (R MB'000)	1,319,063	1,218,310
Total average inpatient spending per bed-day (R MB)	380	389
Outpatients		
Number of outpatient visits	500,570	527,050
Revenue from outpatient services (R'000)	68,199	58,089
Revenue from pharmaceutical sales (R'000)	136	110
Revenue from pharmaceutical sales as a percentage of total outpatient revenue (R'000)	150,144	148,606
Revenue from pharmaceutical sales as a percentage of total outpatient revenue (%)	300	282
Total outpatient revenue (R MB'000)	218,343	206,695
Total average outpatient spending per visit (R MB)	436	392
Total treatment and general healthcare services revenue (R MB'000)	1,214,672	1,119,887
Total pharmaceutical sales revenue (R MB'000)	322,734	305,118

1,319.1
8.3% 2022, 10.7%,
85.8% (2022\ 85.5%).

218.3
5.6% 2022,
5.0%
11.2%.
14.2% (2022\ 14.5%).

8.5% 2022, 79.0% (2022\ 78.6%)
5.8% 2022, 21.0% (2022\ 21.4%)
13.1% (2022\ 12.8%),
68.8% (2022\ 71.9%).

	For the year ended December 31,	
	2023 (R MB'000)	2022 (R '000)
	365,896	339,777
	435,287	390,107
	31,319	33,584
	89,752	99,553
	65,183	63,747
	21,092	20,295
	99,391	93,052
Cost of revenue of owned hospitals	1,107,920	1,040,115

2023.	1,107.9	6.5%
2022.	()	7.7%
	()	11.6%
	()	9.1%
2022.		

33.0% (2022\ 32.7%).

39.3% (2022\ 37.5%).

10.9% (2022\ 12.8%).

105.8

64.4 (2022\ 85.5).

5.3 (2022\ 8.1),

4.1.2 Gross Profit and Gross Profit Margin

2023.	411.1	16.5%
2022.	377.2	15.5%
2022.		

	For the year ended December 31,	
	2023	2022
	25.4%	23.9%
	30.5%	22.2%
Consolidated gross profit margin	25.8%	23.8%

25.8% (2022\ 23.8%), compared to 2022, decreased by 1.5%.

4.1.3 Tax and Surcharge

For the year ended December 31, 2023, the tax and surcharge expense was RMB6.5 million (2022\ RMB5.0 million).

4.1.4 Selling Expenses

For the year ended December 31, 2023, the selling expenses were RMB17.1 million (2022\ RMB15.0 million), an increase of 1.2% compared to 2022 (2022\ 1.1%).

4.1.5 Administrative Expenses

For the year ended December 31, 2023, the administrative expenses were RMB213.0 million, an increase of 3.5% compared to 2022, 205.9 million, an increase of 5.5% compared to 2022. The administrative expenses accounted for 14.3% (2022\ 15.1%).

	For the year ended December 31,	
	2023	2022
	(RMB'000)	(RMB'000)
Salaries and wages	117,426	111,252
Salaries and wages of sales staff	29,101	24,761
Salaries and wages of administrative staff	19,853	29,187
Salaries and wages of support staff	4,725	4,359
Salaries and wages of other staff	41,921	36,328
Total administrative expenses	213,026	205,887

For the year ended December 31, 2023, the administrative expenses were RMB213.0 million, an increase of 3.5% compared to 2022, 205.9 million, an increase of 5.5% compared to 2022. The administrative expenses accounted for 14.3% (2022\ 15.1%).

4.1.6 Research and Development Expenses

Research and development expenses are incurred in the process of developing new products and technologies. These expenses are capitalised and amortised over the useful life of the asset. The following table shows the research and development expenses for the years ended December 31, 2023 and 2022.

	For the year ended December 31,	
	2023 (R MB'000)	2022 (R MB'000)
Salaries and wages	20,552	18,899
Materials and supplies	8,436	9,803
Depreciation and amortisation	3,427	4,053
Other expenses	51	273
Total	32,466	33,028

Research and development expenses for 2023 were RMB 32.5 million (2022: RMB 33.0 million), an increase of 1.7% compared to 2022. This increase was primarily due to an increase in salaries and wages of 8.5% (2022: 2.4%). Other expenses increased by 2.2% (2022: 2.4%).

4.1.7 Finance Expenses – Net

Finance expenses are incurred on the borrowings of the Group. The following table shows the finance expenses for the years ended December 31, 2023 and 2022.

	For the year ended December 31,	
	2023 (R MB'000)	2022 (R MB'000)
Interest on bank borrowings	-5,266	-2,762
Interest on other borrowings	-4	-78
Interest on finance lease	30,180	33,214
Interest on government bonds	9,755	11,936
Interest on other financial assets	5,694	1,180
Other income	1,093	820
Finance expenses – net	41,452	44,310

4.1.10 Non-Operating Income and Non-Operating Expenses

The following table presents the components of non-operating income and non-operating expenses for the years ended December 31, 2023 and 2022. The amounts are presented in RMB'000.

	For the year ended December 31,	
	2023 (RMB'000)	2022 (RMB'000)
Interest income	566	55
Interest expense	5,975	7,436
Net interest income	3,004	1,063
Non-operating income	9,545	8,554
Depreciation and amortization	291	1,588
Provision for doubtful accounts	4,494	3,928
Provision for impairment of financial assets	3,380	1,754
Provision for impairment of non-financial assets	3,201	2,071
Non-operating expenses	11,816	9,341

For the year ended December 31, 2023, the net interest income was 9.5% of the total operating income, compared with 1.0% for the year ended December 31, 2022. For the year ended December 31, 2023, the net interest expense was 26.6% of the total operating income, compared with 53.9% for the year ended December 31, 2022. For the year ended December 31, 2023, the net interest income was 12.4% of the total operating income, compared with 170.3% for the year ended December 31, 2022. For the year ended December 31, 2023, the net interest expense was 2.1% of the total operating income, compared with 0.9% for the year ended December 31, 2022.

4.1.11 Income Tax Expense

The following table presents the components of income tax expense for the years ended December 31, 2023 and 2022. The amounts are presented in RMB'000.

4.2 Financial Position

4.2.1 Inventory

As at 31, 2023, the Company's inventory was \$60.6 million (As at 31, 2022 \$58.3 million), which was comprised of the following:

4.2.2 Accounts Receivables

As at 31, 2023, the Company's accounts receivables were \$420.4 million.

4.2.7 Accounts Payables

At December 31, 2023, accounts payable were \$110.1 million (compared to \$85.8 million at December 31, 2022).

4.2.8 Receipts in Advance and Contract Liabilities

At December 31, 2023, receipts in advance and contract liabilities were \$26.6 million (compared to \$29.9 million at December 31, 2022).

4.2.9 Other Payables

4.3.2 Net Cash Used in Investing Activities

At December 31, 2023, the Company's cash and cash equivalents were 215.0 million, compared with 179.7 million at December 31, 2022. The decrease was primarily due to the purchase of property, plant and equipment, and the purchase of intangible assets, partially offset by the disposal of property, plant and equipment, and the disposal of intangible assets. The Company's cash and cash equivalents were 215.0 million at December 31, 2023, compared with 179.7 million at December 31, 2022.

4.3.3 Net Cash Generated from Financing Activities

At December 31, 2023, the Company's cash and cash equivalents were 215.0 million, compared with 179.7 million at December 31, 2022. The decrease was primarily due to the purchase of property, plant and equipment, and the purchase of intangible assets, partially offset by the disposal of property, plant and equipment, and the disposal of intangible assets. The Company's cash and cash equivalents were 215.0 million at December 31, 2023, compared with 179.7 million at December 31, 2022.

4.3.4 Significant Investment, Acquisition and Disposal

The Company's significant investment, acquisition and disposal activities are as follows:

The Company's significant investment, acquisition and disposal activities are as follows:

4.4 Indebtedness

4.4.1 Bank Borrowings

At December 31, 2023, the Company's bank borrowings were 864.7 million, compared with 616.5 million at December 31, 2022. The increase was primarily due to the increase in bank borrowings, partially offset by the decrease in bank borrowings. The Company's bank borrowings were 864.7 million at December 31, 2023, compared with 616.5 million at December 31, 2022.

4.4.2 Contingent Liability

At December 31, 2023, the Company's contingent liability was 357.7 million, compared with 605.9 million at December 31, 2022. The decrease was primarily due to the decrease in contingent liability, partially offset by the increase in contingent liability. The Company's contingent liability was 357.7 million at December 31, 2023, compared with 605.9 million at December 31, 2022.

4.4.3 Asset Pledge

		826751,	
	826750,	(2016)	
0010144,	(2016)		0010142, (2021)
	0081628,		(2017)
	0018361		
	31, 2023,		
260.0			
	(2020)		0068897
			31, 2023,
	75.1		
	(2023)		
0000180			
31, 2023,		25.0	
			(2022)
	0045588		
	31, 2023,		37.7

4.4.4 Lease Liabilities

31, 2023,	
	28.6
163.2	

4.4.5 Financial Instruments

The Group's financial instruments consist of cash and cash equivalents, trade receivables, trade payables, bank borrowings, and other financial assets and liabilities. The Group's financial instruments are classified as financial assets or financial liabilities.

4.4.6 Exposure to Fluctuation in Exchange Rates

The Group's financial instruments are exposed to foreign exchange risk arising from the use of foreign currencies in the Group's operations. The Group's financial instruments are classified as financial assets or financial liabilities.

At 31, 2023, the Group's financial instruments are exposed to foreign exchange risk arising from the use of foreign currencies in the Group's operations. The Group's financial instruments are classified as financial assets or financial liabilities.

4.4.7 Gearing Ratio

At 31, 2023, the Group's gearing ratio (defined as the ratio of the Group's total debt to the Group's total capital) was 53.8% (at 31, 2022: 49.7%).

6 PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

State of Georgia, County of DeKalb, ss. I, _____, Clerk of the Superior Court, do hereby certify that _____ is the duly qualified and acting Clerk of the Superior Court of the County of DeKalb, State of Georgia.

10, 2023, (Mr. Zhao)
 3.10
 3.25
 3.27
 10, 2023, (Ms. Jin)
 2022
 9, 2023.
 3.10, 3.25, 3.27

9 COMPLIANCE WITH THE MODEL CODE

10 EVENTS AFTER THE REPORTING PERIOD

11 AUDITORS AND WORKING SCOPE

2023,

31, 2023,
 2023.

12 FINANCIAL REPORT

12.1 Accounting Policies

the Company has adopted the Accounting Standards for Business Enterprises (CAS) issued by the Ministry of Finance of the PRC on July 15, 2006, and the subsequent amendments (collectively referred to as "the Accounting Standards for Business Enterprises" or "CAS").

12.1.1 Changes in significant accounting policies and accounting estimates

12.1.1.1 Changes in accounting policies

During the reporting period, the Company has adopted the Accounting Standards for Business Enterprises (CAS) issued by the Ministry of Finance of the PRC on July 15, 2006, and the subsequent amendments (collectively referred to as "the Accounting Standards for Business Enterprises" or "CAS").

On December 30, 2022, the Company has adopted the Accounting Standards for Business Enterprises (CAS) issued by the Ministry of Finance of the PRC on July 15, 2006, and the subsequent amendments (collectively referred to as "the Accounting Standards for Business Enterprises" or "CAS").

During the reporting period, the Company has adopted the Accounting Standards for Business Enterprises (CAS) issued by the Ministry of Finance of the PRC on July 15, 2006, and the subsequent amendments (collectively referred to as "the Accounting Standards for Business Enterprises" or "CAS").

12.2 Annual Consolidated Financial Information

12.2.1 Annual Consolidated Income Statement

(continued from page 10)

Items	Year ended December 31,	
	2023	2022
I. Total revenue	1,596,265,532	1,484,903,042
Revenue from sales of products	1,596,265,532	1,484,903,042
Revenue from services	—	—
Revenue from other sources	—	—
	1,596,265,532	1,484,903,042
II. Total cost of sales	1,495,651,128	1,435,161,134
Cost of sales of products	1,185,129,955	1,131,971,943
Cost of sales of services	—	—
Cost of sales of other sources	—	—
	1,495,651,128	1,435,161,134
III. Total operating expenses	213,025,707	205,887,172
Depreciation and amortization	32,466,196	33,027,988
Salaries and benefits	41,452,011	44,309,717
Research and development	39,936,115	45,149,998
Marketing and sales	5,265,571	2,761,765
General and administrative	—	—
Interest expense	—	—
Other operating expenses	—	—
	213,025,707	205,887,172
IV. Total operating income	6,474,904	4,960,286
Income from operations	17,102,355	15,004,028
Income from other sources	—	—
Income from discontinued operations	—	—
	17,102,355	15,004,028
V. Total income before taxes	213,025,707	205,887,172
Income tax expense	32,466,196	33,027,988
	41,452,011	44,309,717
VI. Total income after taxes	39,936,115	45,149,998
Income from operations	5,265,571	2,761,765
Income from other sources	—	—
Income from discontinued operations	—	—
	5,265,571	2,761,765

Items	Year ended December 31,	
	2023	2022
Net profit (net losses represented with “-” signs)	15,976,715	14,907,711
1. Profit (loss) from operations	(6,067,197)	2,850,458
2. Profit (loss) from other operations	(6,465,279)	(15,926,847)
3. Profit (loss) from discontinued operations	—	—
4. Profit (loss) from equity investments	—	—
5. Profit (loss) from other non-operating activities	—	—
6. Profit (loss) from other non-operating activities	214,405	(15,977,326)
7. Profit (loss) from other non-operating activities	(9,354,736)	(25,191,541)
8. Profit (loss) from other non-operating activities	—	(10,345,461)
9. Profit (loss) from other non-operating activities	68,089	406,185
III. Operating profit (losses represented with “-” signs)	101,451,680	16,391,934
1. Profit (loss) from operations	9,545,446	8,553,978
2. Profit (loss) from other operations	11,815,509	9,341,039
IV. Total profit (total losses represented with “-” signs)	99,181,617	15,604,873
1. Profit (loss) from operations	12,250,009	26,573,712
V. Net profit (net losses represented with “-” signs)	86,931,608	(10,968,839)
1. Profit (loss) from operations	86,931,608	(10,968,839)
2. Profit (loss) from other operations	—	—
3. Profit (loss) from discontinued operations	—	—
4. Profit (loss) from equity investments	85,947,807	(24,220,782)
5. Profit (loss) from other non-operating activities	983,801	13,251,944

Items	Year ended December 31,	
	2023	2022
VI. Other comprehensive income, net of tax		
Income tax expense on other comprehensive income		
() Income tax expense on other comprehensive income		
1. Income tax expense on other comprehensive income	-	
2. Income tax expense on other comprehensive income		
3. Income tax expense on other comprehensive income	-	
4. Income tax expense on other comprehensive income	-	
() Income tax expense on other comprehensive income		
1. Income tax expense on other comprehensive income	-	
2. Income tax expense on other comprehensive income	-	
3. Income tax expense on other comprehensive income	-	
4. Income tax expense on other comprehensive income	-	
5. Income tax expense on other comprehensive income	-	
6. Income tax expense on other comprehensive income	-	
7. Income tax expense on other comprehensive income	-	
Income tax expense on other comprehensive income	-	
Income tax expense on other comprehensive income		
VII. Total comprehensive income	86,931,608	-10,968,838
Income tax expense on other comprehensive income	85,947,807	-24,220,782
Income tax expense on other comprehensive income	983,801	13,251,944
VIII. Earnings per share:		
() Income tax expense on other comprehensive income	1.15	-0.32
() Income tax expense on other comprehensive income	1.15	-0.32

12.2.2 Annual Consolidated Balance Sheets

(Amounts in millions of U.S. dollars)

	December 31, 2023	December 31, 2022
ASSETS		
Current assets:		
Cash and cash equivalents	418,861,721	271,094,963
Accounts receivable	—	—
Prepaid expenses and other receivables	—	—
Inventory	7,350,299	10,641,026
Other current assets	—	—
Investments	420,441,070	382,836,691
Goodwill	—	—
Intangible assets	9,830,553	32,201,224
Other non-current assets	—	—
Deferred tax assets	—	—
Other non-current assets	—	—
Other non-current assets	69,705,729	37,195,220
Other non-current assets	—	—
Other non-current assets	60,600,180	58,331,397
Other non-current assets	—	—
Other non-current assets	—	—
Other non-current assets	—	—
Other non-current assets	858,020	752,325
Total current assets	987,647,572	793,052,846

ASSETS	December 31, 2023	December 31, 2022
Non-current assets:		
Land	—	—
Land held for sale	—	—
Investment in real estate	—	—
Investment in real estate	14,000,000	14,000,000
Investment in real estate	139,071,987	143,546,246
Investment in real estate	—	—
Investment in real estate	65,099,055	63,116,852
Investment in real estate	—	—
Investment in real estate	794,856,343	695,020,441
Investment in real estate	186,980,241	152,497,400
Investment in real estate	—	—
Investment in real estate	—	—
Investment in real estate	189,054,507	190,403,752
Investment in real estate	320,321,705	254,684,348
Investment in real estate	—	—
Investment in real estate	119,909,089	107,655,738
Investment in real estate	175,910,626	189,586,339
Investment in real estate	45,146,271	20,682,398
Investment in real estate	9,689,211	13,541,047
Total non-current assets	2,060,039,035	1,844,734,561
TOTAL ASSETS	3,047,686,607	2,637,787,407

LIABILITIES AND SHAREHOLDERS' EQUITY

**December 31,
2023** **December 31,
2022**

Current liabilities:

Accounts payable	127,001,700	203,000,000
Accounts receivable	—	—
Prepaid expenses	—	—
Deferred revenue	12,400,000	13,922,929
Other current liabilities	—	—
Income taxes payable	1,545,021	997,944
Other current liabilities	110,060,008	85,773,062
Other current liabilities	26,563,603	29,894,837
Other current liabilities	—	—
Other current liabilities	—	—
Other current liabilities	—	—
Other current liabilities	—	—
Other current liabilities	—	—
Other current liabilities	84,324,006	70,588,350
Other current liabilities	38,553,746	33,507,164
Other current liabilities	150,270,575	72,193,730
Other current liabilities	—	—
Other current liabilities	—	—
Other current liabilities	—	—
Other current liabilities	250,411,757	147,598,324
Other current liabilities	—	—
Total current liabilities	801,130,416	657,446,340

LIABILITIES AND SHAREHOLDERS' EQUITY	December 31, 2023	December 31, 2022
Non-current liabilities:		
Long-term debt	557,719,215	391,010,000
Deferred income taxes	—	—
Other non-current liabilities	—	—
Total non-current liabilities	163,239,533	171,437,740
Current liabilities	61,351,341	42,404,938
Total liabilities	8,734,099	9,037,891
Shareholders' equity:	47,306,056	40,547,879
Common stock	—	—
Preferred stock	—	—
Additional paid-in capital	—	—
Retained earnings	—	—
Total shareholders' equity	838,350,244	654,438,448
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	1,639,480,660	1,311,884,788

12.2.3 Annual Consolidated Statements of Cash Flow

($\frac{1}{2} \leq x_1 < 1$, $\frac{1}{2} \leq x_2 < 1$, $\frac{1}{2} \leq x_3 < 1$, $\frac{1}{2} \leq x_4 < 1$)

[illegible]

Items	Year ended December 31,	
	2023	2022
II. Cash flows from investing activities		
Proceeds from the sale of property, plant and equipment	8,279,458	-
Proceeds from the sale of investments	-	1,650,804
Proceeds from the sale of investments, net of transaction costs	2,924,937	24,100,367
Proceeds from the sale of investments, net of transaction costs	1,248,000	-
Sub-total of cash inflows of investing activities	12,452,395	25,751,171
Proceeds from the sale of investments, net of transaction costs	179,732,394	236,910,179
Proceeds from the sale of investments, net of transaction costs	2,447,873	-
Proceeds from the sale of investments, net of transaction costs	-	-
Sub-total of cash inflows of investing activities	31,289,153	-

Items	Year ended December 31,	
	2023	2022
III. Cash flows from financing activities		
Proceeds from the issuance of bank loans	2,999,500	9,153,084
Proceeds from the issuance of corporate bonds	2,999,500	9,153,084
Proceeds from the issuance of corporate bonds	605,774,670	387,500,000
Proceeds from the issuance of corporate bonds	55,900,000	151,420,250
Sub-total of cash inflows of financing activities	664,674,170	548,073,334
Interest paid on bank loans	357,677,873	324,220,000
Interest paid on corporate bonds	35,398,809	51,554,508
Interest paid on corporate bonds	3,001,921	
Interest paid on corporate bonds	175,490,617	56,121,295
Sub-total of cash outflows of financing activities	568,567,299	431,895,803
Net cash flows from financing activities	96,106,871	116,177,531
IV. Effect of foreign exchange rate changes on cash and cash equivalents	4,325	78,463
V. Net increase in cash and cash equivalents	146,127,348	69,861,145
Net increase in cash and cash equivalents	258,595,991	188,734,846
VI. Cash and cash equivalents at the end of the period	404,723,339	258,595,991

12.2.4 Consolidated Statement of Changes in Shareholders' Equity

(Amount in million Japanese Yen)

Items	Other equity instruments				Amount for the current period										Non – controlling interests	Total owners’ equity
	Share capital	Preferred shares	Perpetual bonds	Others	Equity attributable to owners of the parent company							Subtotal				
					Capital reserve	Less: Treasury stock	Other comprehensive income	Special reserve	Surplus reserve	Provision for general risk	Retained earnings					
At January 1, 2019	74,600,300	-	-	-	855,078,533	-	-	-	38,399,577	-	233,056,534	1,201,584,944	124,317,674	1,325,902,618		
Net income	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Other comprehensive income	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Dividends paid	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Share-based payment	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Share repurchase	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
At December 31, 2019	74,600,300	-	-	-	855,078,533	-	-	-	38,399,577	-	233,506,534	1,201,584,944	124,317,674	1,325,902,618		
Net income	-	-	-	-	-2,382,932	12,587,012	-	-	-	-	78,449,695	63,479,752	18,823,577	82,303,329		
(-) Dividends paid	-	-	-	-	-	-	-	-	-	-	85,947,807	85,947,807	983,801	86,931,608		
(-) Dividends paid to non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-12,587,012	20,730,697	8,143,685		
1. Dividends paid to shareholders	-	-	-	-	-	-	-	-	-	-	-	-12,587,012	20,730,697	8,143,685		
2. Dividends paid to non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
3. Dividends paid to employees	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
4. Dividends paid to directors	-	-	-	-	-	-	-	-	-	-	-	-	-	-		

Items	Amount for the current period														
	Other equity instruments				Equity attributable to owners of the parent company								Non – controlling interests	Total owners’ equity	
	Share capital	Preferred shares	Perpetual bonds	Others	Capital reserve	Less:	Other	Special reserve	Surplus reserve	Provision for general risk	R etained earnings	Subtotal			
						Treasury stock	comprehensive income								
(一) 所有者权益合计	-	-	-	-	-	-	-	-	-	-	-	-7,498,112	-7,498,112	-2,890,921	-10,389,033
1. 实收资本(股本)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2. 其他权益工具	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3. 所有者权益合计(一)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4. 其他	-	-	-	-	-	-	-	-	-	-	-	-7,498,112	-7,498,112	-2,890,921	-10,389,033
(二) 所有者权益增减变动情况	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
1. 所有者权益增减变动情况	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2. 所有者权益增减变动情况	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3. 所有者权益增减变动情况	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4. 所有者权益增减变动情况	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5. 所有者权益增减变动情况	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6. 其他	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Items	Amount for the current period									
	Other equity instruments				Equity attributable to owners of the parent company					
	Share capital	Preferred shares	Perpetual bonds	Others	Capital reserve	Treasury stock	Less:	Other	Special reserve	Surplus reserve
							comprehensive income			
									Provision for general risk	Retained

12.3 Notes to the Consolidated Annual Financial Information prepared in accordance with the China Accounting Standard for Business Enterprises

12.3.1 Accounts receivable

The aging analysis of accounts receivables based on the billing date is as follows:

	December 31, 2023 RMB	December 31, 2022
Within 1 year	425,833,221	388,961,193
1 - 2 years	6,696,710	4,755,920
2 - 3 years	4,480,033	3,941,367
Over 3 years	7,780,010	5,180,894
Subtotal	444,789,973	402,839,374
Accounts receivable with no expected recovery	24,348,904	20,002,683
Accounts receivable	420,441,070	382,836,691

		December 31, 2022		December 31, 2021	
		Amount	Weighted average (%)	Amount	Weighted average (%)
Accounts receivable					
Accounts receivable		18,221,976	4.5	12,514,143	67.7
Allowance for doubtful accounts		18,221,976	4.5	12,514,143	68.7
Accounts receivable, net					
Accounts receivable		384,617,398	95.5	7,488,540	2.0
Allowance for doubtful accounts		384,617,398	95.5	7,488,540	2.0
Accounts receivable, net		<u>402,839,374</u>	<u>100.0</u>	<u>20,002,683</u>	<u>5.0</u>

12.3.2 Accounts payable

		December 31, 2023	December 31, 2022
		₹ MB	₹ MB
Accounts payable			
Accounts payable		107,790,035	84,193,739
Accounts payable		1,815,169	1,161,389
Accounts payable		85,740	71,969
Accounts payable		<u>369,064</u>	<u>345,965</u>
Accounts payable		<u>110,060,008</u>	<u>85,773,062</u>

12.3.3 **R**evenue and cost of sales

Analysis of revenue and cost of sales

	Year ended December 31, 2023		Year ended December 31, 2022	
	R evenue	Cost		
Revenue	1,485,160,595	1,107,920,077	1,366,816,938	1,040,114,650
Cost of sales	<u>111,104,937</u>	<u>77,209,878</u>	<u>118,086,104</u>	<u>91,857,293</u>
Profit	<u>1,596,265,532</u>	1,185,129,955	1,484,903,042	1,131,971,943

12.3.4 Credit impairment losses

	Year ended December 31,	
	2023	2022
Impairment losses on financial assets	7,172,896	11,260,563
Impairment losses on investment properties	2,181,839	13,930,978
	<u>9,354,735</u>	<u>25,191,541</u>

12.3.5 Earning per Share

Basic earning per Share

	Year ended December 31,	
	2023	2022
Profit attributable to equity holders of the Company	85,947,807	-24,220,782
Profit attributable to equity holders of the Company	74,600,300	74,600,300
Weighted average number of shares outstanding	1.15	-0.32
Weighted average number of shares outstanding	1.15	-0.32
Weighted average number of shares outstanding	—	—

Diluted earning per Share

	Year ended December 31,	
	2023	2022
Profit attributable to equity holders of the Company (continued)	85,947,807	-24,220,782
Profit attributable to equity holders of the Company (continued)	74,600,300	74,600,300
Weighted average number of shares outstanding	1.15	-0.32
Weighted average number of shares outstanding	1.15	-0.32
Weighted average number of shares outstanding	—	—

12.3.6 Income tax expenses

Table of income tax expenses

	Year ended December 31,	
	2023	2022
Profit before income tax	36,259,411	40,192,565
Income tax expense	-24,009,402	-13,618,853
	12,250,009	26,573,172

R econciliation between total profit and income tax expenses

	Year ended December 31,	
	2023	2022
Profit before income tax	99,181,617	15,604,874
Income tax expense	19,960,640	3,028,480
Income tax expense	-223,220	7,125,277
Income tax expense	-189,327	-3,896,947
Income tax expense	3,879,078	-5,563,847
Income tax expense	2,133,262	1,736,913
Income tax expense	-18,633,562	137,339
Income tax expense	13,333,667	31,726,873
Income tax expense	-4,674,287	-4,141,335
Income tax expense	-1,945,480	-2,298,769
Income tax expense	-1,390,762	-1,280,272
	12,250,009	26,573,712

12.3.7 Dividend

On December 28, 2024, the Board of Directors declared a cash dividend of \$0.10 per share to the holders of record of the common stock as of December 31, 2023, totaling \$22,380,090 (including \$74,600,300 of accrued dividends payable as of December 31, 2023).

The dividend was paid on January 31, 2023, to the holders of record of the common stock as of December 30, 2023, totaling \$7,460,030 (including \$74,600,300 of accrued dividends payable as of December 30, 2023). The dividend was paid to the holders of record of the common stock as of December 27, 2023.

On January 14, 2023, the Board of Directors declared a cash dividend of \$0.10 per share to the holders of record of the common stock as of December 31, 2022, totaling \$7,460,030 (including \$74,600,300 of accrued dividends payable as of December 31, 2022). The dividend was paid on January 9, 2023.

13 DEFINITIONS

Unless otherwise specified, all amounts are in U.S. dollars and all years are 2023.

附註	2017年12月31日	2016年12月31日
1. 現金及現金等價物	1,000,000	1,000,000
2. 應收賬款	1,000,000	1,000,000
3. 應付賬款	1,000,000	1,000,000
4. 應收票據	1,000,000	1,000,000
5. 應付票據	1,000,000	1,000,000
6. 其他應收款	1,000,000	1,000,000
7. 其他應付款	1,000,000	1,000,000
8. 長期應收款	1,000,000	1,000,000
9. 長期應付款	1,000,000	1,000,000
10. 其他資產	1,000,000	1,000,000
11. 其他負債	1,000,000	1,000,000
12. 股本	1,000,000	1,000,000
13. 資本公積金	1,000,000	1,000,000
14. 盈餘	1,000,000	1,000,000
15. 其他權益	1,000,000	1,000,000
16. 總計	1,000,000	1,000,000

11/11/2020

... (溫州慈寧醫院有限公司),
J, 25,
2006,

... (溫州甌海怡寧老年
醫院有限公司),
8, 2021,

... (怡寧心理
互聯網醫院(溫州)有限公司
10, 2020,

... (永嘉康寧醫院有限公司),
12,
2012,

樂清康寧醫院有限公司),
3,

結合醫院有限公司),
4, 2006,

(樂

ou Kangning Hospital Co., Ltd.
GUAN Weili

28, 2024

J,
J,
J,